DV
Dividend Vision

BDSX — Biodesix Inc

Biodesix Inc (BDSX)

Total return is -90.6% over the past 5.8 years, 247.6 points behind SPY at 157.0%. Its deepest 1-year drawdown was 49.3%.

Biodesix, Inc. is a diagnostic solutions company that develops blood-based lung cancer tests, including the Nodify XL2 and Nodify CDT tests for lung nodule risk assessment, as well as genomic testing solutions like GeneStrat and VeriStrat to guide treatment decisions. The company also provides research and development services to biopharmaceutical and diagnostic companies. Biodesix does not currently distribute dividends and is oriented toward investors seeking exposure to the diagnostics and precision medicine sector rather than income generation.

BDSX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/28/2020
Last close
$24.00
Market cap
$209,083,792
Average volume
72400.0
Beta
0.523
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.96